Bayer (BAYN) Given a €125.00 Price Target at UBS Group
UBS Group set a €125.00 ($154.32) price objective on Bayer (FRA:BAYN) in a report released on Monday, www.boersen-zeitung.de reports. The brokerage currently has a buy rating on the healthcare company’s stock.
BAYN has been the subject of several other research reports. S&P Global set a €126.00 ($155.56) price objective on Bayer and gave the stock a buy rating in a research report on Thursday, October 26th. Sanford C. Bernstein set a €131.00 ($161.73) price objective on Bayer and gave the stock a buy rating in a research report on Wednesday, November 29th. DZ Bank reissued a buy rating on shares of Bayer in a research report on Monday, December 11th. equinet set a €118.00 ($145.68) price objective on Bayer and gave the stock a buy rating in a research report on Friday, October 13th. Finally, Independent Research set a €120.00 ($148.15) price target on Bayer and gave the company a neutral rating in a research note on Friday, October 13th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of €121.71 ($150.26).
Bayer (FRA:BAYN) opened at €97.62 ($120.52) on Monday. Bayer has a 12-month low of €93.30 ($115.19) and a 12-month high of €123.82 ($152.86). The firm has a market capitalization of $80,480.00 and a PE ratio of 23.08.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.